Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

@article{Baron2008CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial},
  author={J. Baron and R. Sandler and R. Bresalier and {\'A}. Lanas and D. Morton and R. Riddell and E. Iverson and D. DeMets},
  journal={The Lancet},
  year={2008},
  volume={372},
  pages={1756-1764}
}
BACKGROUND Selective inhibition of cyclo-oxygenase-2 has been associated with an increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp Prevention on Vioxx (APPROVe) study assessed the effect of 3-year treatment with a cyclo-oxygenase-2 inhibitor, rofecoxib (25 mg), on recurrence of neoplastic polyps of the large bowel. We report the cardiovascular outcomes of a long-term follow-up of participants in the trial. METHODS The APPROVe study is a multicentre… Expand
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
TLDR
Intention-to-treat analysis of placebo-controlled studies of rofecoxib for Alzheimer disease demonstrated that the drug produced a significant increase in confirmed CVT deaths nearly 40 months before it was removed from the market. Expand
Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case–control study
TLDR
The overall rate of cerebrovascular event was not elevated with current NSAIDs overall when compared with past use, but diclofenac and ketoprofen seemed to increase the risk of cereBrovascular events. Expand
Clinical Pharmacology and Cardiovascular Safety of Naproxen
TLDR
The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2Selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs. Expand
The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.
TLDR
The cardiovascular risk associated with NSAID treatment was prevalent at start of treatment, suggesting no safe treatment window for NSAIDs in patients with cardiovascular disease, and evidence from observational studies is accumulating, suggesting that NSAIDs are a major public health concern due to the widespread use. Expand
Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults—a nationwide registry-based study
TLDR
This Icelandic nationwide registry-based study showed increased risk of cardiovascular events, i.e. cerebralinfarction, myocardial infarction and unstable angina pectoris, among rofecoxib and naproxen users in comparison to diclofenac users. Expand
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance.
TLDR
Cumulative pooled analysis of all randomized, placebo-controlled trials demonstrates a trend toward increased cardiovascular risk associated with rofecoxib compared with placebo as early as December 2000, the comparison reaching a P value of .05 by June 2001, nearly 3(1/2) years before the manufacturer's voluntary market withdrawal. Expand
Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals
TLDR
Individual NSAIDs have different cardiovascular safety that needs to be considered when choosing appropriate treatment and should be used with caution in most individuals, underlines the importance of critical use of NSAID therapy in the general population and that over-the-counter retail of NSAIDs should be reassessed. Expand
Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
TLDR
There is insufficient evidence to conclude that there are significant differences between the approved NSAIDs with regard to the potential for cardiovascular events, and clinicians should continue to use the current FDA NSAID labeling language to guide their decision making for individual patients. Expand
An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs.
TLDR
It is important that cardiologists, who are not among those physicians frequently prescribing NSAIDs, have a particular responsibility to have up-to-date, thoughtfully synthesized information about the CV risks of these drugs, especially when administered to patients receiving low-dose aspirin for cardioprotection. Expand
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials.
TLDR
The clinical data and plausible mechanisms of CV hazards associated with traditional NSAIDs and coxibs are discussed, and the use of low-dose aspirin may have a place for chemoprevention of CRCs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
TLDR
Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk, and cardiovascular mortality was similar in the two groups. Expand
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
TLDR
Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration, and died from cardiovascular causes during the follow-up period. Expand
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
TLDR
A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs. Expand
Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas
Background— Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk. Methods and Results— The Adenoma PreventionExpand
Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
TLDR
In patients undergoing coronary artery bypass grafting surgery, the cyclooxygenase 2 inhibitor combination, parecoxib/valdecoxib, was effective for postoperative analgesia, however, the 14-day treatment regimen also was associated with an increased incidence of serious adverse events overall and sternal wound infections in particular. Expand
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
TLDR
A pooled analysis from 23 studies encompassing multiple disease states and including more than 14,000 patient-years at risk demonstrated that rofecoxib was not associated with excess CV thrombotic events compared with either placebo or nonnaproxen NSAIDs. Expand
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
TLDR
It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug. Expand
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
TLDR
The use of parecoxib and valdecoxib after CABG was associated with an increased incidence of cardiovascular events, arousing serious concern about the use of these drugs in such circumstances. Expand
Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
TLDR
In this comprehensive analysis of 114 randomized trials with 116,094 participants, rofecoxib was associated with increased renal and arrhythmia risks and a COX-2 inhibitor class effect was not evident. Expand
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
TLDR
Selective COX 2 inhibitors are associated with a moderate increase in the risk of vascular events, as are high dose regimens of ibuprofen and diclofenac, but high dose naproxen is not associated with such an excess. Expand
...
1
2
3
4
...